查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物技术合约製造的全球市场：按服务（製造、填充、包装）、按类型（活性药物成分、产品）、按业务规模、按来源（哺乳动物）、按治疗领域（肿瘤学）、按分子类型（ mAb)、ADC、CGT、疫苗) - 2028 年预测
市场调查报告书
商品编码
1350662

生物技术合约製造的全球市场：按服务（製造、填充、包装）、按类型（活性药物成分、产品）、按业务规模、按来源（哺乳动物）、按治疗领域（肿瘤学）、按分子类型（ mAb)、ADC、CGT、疫苗) - 2028 年预测

Biotechnology Contract Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecasts to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 324 Pages | 订单完成后即时交付

价格
简介目录

生技合约製造市场规模预计将从 2023 年的 166 亿美元增至 2028 年的 248 亿美元，2023-2028 年预测期间年复合成长率为 8.3%。

该市场的成长归因于製药公司和生物製剂合约製造商之间的伙伴关係和合作数量的增加。例如，2023年1月，Catalent（美国）宣布Sarepta Therapeutics, Inc.（美国）和Sarepta Therapeutics, Inc.（美国）宣布Sarepta的领先基因治疗候选药物derandystrogen moxeparvovec (SRP-9001)，用于治疗杜氏肌肌肉萎缩症。我们已经签订了生产合约。同样，2022年12月，默克公司（德国）和Synprogen（日本）签署协议，加速利用病毒载体开发和製造基因治疗药物。

2022年，单株抗体领域在全球生物技术合约製造市场中按分子计算占据最大份额。该细分市场的大部分份额归因于疾病患病的上升、政府开发单株抗体医药品的倡议的增加以及目前临床管道中的单株抗体产品候选数量的增加。

在生物技术合约製造市场中，欧洲是仅次于北美的第二大市场。由于多种要素的影响，欧洲生物技术合约製造市场近年来经历了显着增长，包括增加投资开拓单株抗体、细胞和基因疗法药物等生物製品市场，以及扩大生物製造能力。欧洲处于生物技术合约製造市场新技术开发和实施的前沿。 2023 年 3 月，龙沙建成了专门用于大规模商业药品生产的 cGMP 临床和商业生产基地。

这份报告考察了全球生物技术合约製造市场，包括按服务、类型、业务规模、起源、治疗领域、分子类型、地区和进入市场的公司概况分類的趋势。我对此进行了总结。

目录

第1章简介

第2章调查方法

第3章执行摘要

第4章重要考察

第5章市场概况

  • 介绍
  • 市场动态
  • 价值链分析
  • 生态系分析
  • 波特五力分析
  • 技术分析
  • 法规分析
  • 2023-2024年重大会议和活动
  • 主要相关人员和采购标准
  • 影响客户业务的趋势/干扰

第6章生物技术合约製造市场（按服务）

  • 介绍
  • 製造业
  • 混炼和填充完成
  • 包装和标籤
  • 其他的

第7章生物技术合约製造市场，依类型

  • 介绍
  • 生物原料药製造
  • 生物製品製造

第8章生物技术合约製造市场（按业务规模）

  • 介绍
  • 商业的
  • 临床

第9章生物技术合约製造市场（按来源）

  • 介绍
  • 哺乳动物表现系统
  • 非哺乳动物表现系统

第10章生物技术合约製造市场（按分子类型）

  • 介绍
  • 单株抗体
  • 细胞和基因治疗
  • 抗体药物复合体
  • 疫苗
  • 治疗性胜胜肽和蛋白质
  • 其他的

第11章生物技术合约製造市场（按治疗领域）

  • 介绍
  • 瘤
  • 自体免疫疾病
  • 代谢性疾病
  • 心血管疾病
  • 神经科
  • 感染疾病
  • 其他的

第12章生物技术合约製造市场（按地区）

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第13章竞争形势

  • 介绍
  • 收入份额分析
  • 市占率分析
  • 企业评价矩阵
  • 竞争基准化分析
  • 新创公司/中小企业的企业评估矩阵
  • 新兴企业/中小企业的竞争基准化分析
  • 竞争格局及趋势

第14章公司简介

  • 主要参与企业
    • LONZA
    • THERMO FISHER SCIENTIFIC INC.
    • WUXI BIOLOGICS
    • CATALENT, INC.
    • SAMSUNG BIOLOGICS
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • FUJIFILM HOLDINGS CORPORATION
    • ABBVIE INC.
    • EUROFINS SCIENTIFIC
    • GENSCRIPT BIOTECH CORPORATION
    • AGC INC.
    • MERCK KGAA
    • JSR CORPORATION
  • 其他公司
    • STELIS
    • RECIPHARM AB
    • EMERGENT
    • SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.
    • LOTTE BIOLOGICS
    • HEPALINK GROUP
    • CURIA GLOBAL, INC.
    • JRS PHARMA
    • MINAPHARM PHARMACEUTICALS
    • RENTSCHLER BIOPHARMA SE
    • AVID BIOSERVICES, INC.
    • ABZENA LTD.
    • POLYPLUS TRANSFECTION
    • MIDAS PHARMA GMBH
    • MABPLEX INTERNATIONAL CO., LTD.
    • ASAHI KASEI CORPORATION

第15章附录

简介目录
Product Code: BT 8780

The biotechnology contract manufacturing market is estimated to reach USD 24.8 billion by 2028 from USD 16.6 billion in 2023, at a CAGR of 8.3% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing partnerships and collaborations between pharmaceutical companies and biologics contract manufacturers. For instance, In January 2023, Catalent (US) entered into an agreement with Sarepta Therapeutics, Inc. (US) for manufacturing of Sarepta's most advanced gene therapy candidate, delandistrogene moxeparvovec (SRP-9001) for the treatment of Duchenne muscular dystrophy. Similarly, In December 2022, Merck KGaA (Germany) and Synplogen (Japan) entered into an agreement to accelerate the development and manufacturing of viral vector-based gene therapy applications.

"The monoclonal antibodies segment accounted for the largest share by molecule type during the forecast period."

In 2022, the monoclonal antibodies segment accounted for the largest share by molecules in the global biotechnology contract manufacturing market. The large share of this segment is attributed to the rising prevalence of diseases, increasing government initiatives for the development of monoclonal antibody drugs, and the growing number of mAb product candidates currently in the clinical pipeline.

"Europe: The second largest region in the biotechnology contract manufacturing market"

Europe accounted for the second-largest market for biotechnology contract manufacturing market after North America. The European biotechnology contract manufacturing market has experienced substantial growth in recent years, driven by various factors such as increasing investments for the development of biologics such as monoclonal antibodies and cell & gene therapies and biomanufacturing capacity expansions. Europe is at the forefront of developing and adopting emerging technologies in the field of biotechnology contract manufacturing market. In March 2023, Lonza completed its cGMP clinical and commercial manufacturing site, which is dedicated to large-scale commercial drug product manufacturing.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 70% and Demand Side - 30%
  • By Designation: Managers - 45%, CXO and Directors - 30%, and Executives - 25%
  • By Region: North America - 40%, Europe - 25%, Asia-Pacific - 20%, Latin America - 10% and Middle East & Africa - 5%

List of Companies Profiled in the Report:

  • Lonza (Switzerland)
  • Thermo Fisher Scientific Inc. (US)
  • Catalent, Inc. (US)
  • Samsung Biologics (South Korea)
  • WuXi Biologics (China)
  • Boehringer Ingelheim International GmbH (Germany)
  • FUJIFILM Holdings Corporation (Japan)
  • AbbVie, Inc. (US)
  • Eurofins Scientific (Luxembourg)
  • GenScript Biotech Corporation (US)
  • AGC, Inc. (Japan)
  • Merck KGaA (Germany)
  • JSR Corporation (Japan)
  • Stelis (India)
  • Recipharm AB (Sweden)
  • Emergent (US)
  • Shanghai Fosun Pharmaceutical Co., Ltd. (China)
  • LOTTE BIOLOGICS (South Korea)
  • Hepalink Group (China)
  • Curia Global, Inc. (US)
  • JRS Pharma (Germany)
  • MINAPHARM Pharmaceuticals (Egypt)
  • Rentschler Biopharma SE (Germany)
  • Avid Bioservices, Inc. (US)
  • Abzena Ltd. (US)
  • Polyplus Transfection (Germany)
  • Midas Pharma GmbH (Germany)
  • MabPlex International Co., Ltd. (China)
  • Asahi Kasei Corporation (Japan)

Research Coverage:

This report provides a detailed picture of the biotechnology contract manufacturing market. It aims to estimate the size and future growth potential of the market across different segments such as the service, type, scale of operation, source, molecule type, therapeutic area, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing demand for biologics & biosimilars, Increased biologics outsourcing trend among biopharmaceutical companies, Increased focus on personalized medicine, Increasing partnerships and collaborations between pharmaceutical companies and biologics CDMOs), restraints (intellectual property rights issues), opportunities (Rising demand for cell & gene therapy, biologics contract manufacturing market expansions in emerging countries, expansion of biologics manufacturing capacities by CMOs, strong emphasis on drug development), and challenges (challenges to meet reformed regulations) influencing the growth of the market.
  • Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the biotechnology contract manufacturing market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biotechnology contract manufacturing market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), WuXi Biologics (China), AbbVie, Inc. (US), and others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION AND SCOPE
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
    • 1.2.2 MARKETS COVERED
    • 1.2.3 YEARS CONSIDERED
  • 1.3 CURRENCY
  • 1.4 STAKEHOLDERS
  • 1.5 LIMITATIONS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 3 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 - REVENUE SHARE ANALYSIS, 2022
    • FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS, 2022
    • 2.2.1 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
    • FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: CAGR PROJECTIONS
    • FIGURE 9 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 RECESSION IMPACT ANALYSIS
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 11 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 14 GEOGRAPHICAL SNAPSHOT OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET

4 PREMIUM INSIGHTS

  • 4.1 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET OVERVIEW
    • FIGURE 15 RISING APPROVALS OF BIOLOGICS TO DRIVE MARKET
  • 4.2 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE, BY SCALE OF OPERATION & COUNTRY (2022)
    • FIGURE 16 COMMERCIAL OPERATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
  • 4.3 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028
    • FIGURE 17 ONCOLOGY SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028
  • 4.4 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 18 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2028
  • 4.5 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 20 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 4 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising demand for biologics and biosimilars
    • FIGURE 21 NUMBER OF APPROVED BIOLOGICS, 2015-2022
    • FIGURE 22 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015-2022
      • 5.2.1.2 Increasing outsourcing of biologics manufacturing among biopharmaceutical companies
      • 5.2.1.3 Growing focus on personalized medicine
    • FIGURE 23 PERSONALIZED MEDICINES (% OF ALL FDA-APPROVED DRUGS), 2015-2022
      • 5.2.1.4 Increasing collaborations between pharmaceutical companies and biologics CMOs
      • 5.2.1.5 Advancements in manufacturing technologies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Intellectual property rights issues
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for cell and gene therapies
    • TABLE 5 LIST OF EXPANSIONS BY TOP COMPANIES
      • 5.2.3.2 Significant growth opportunities offered by emerging countries
      • 5.2.3.3 Expansion of biologics manufacturing capacities by CMOs
      • 5.2.3.4 Strong emphasis on drug development
    • TABLE 6 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complying with regulatory reforms
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 24 VALUE CHAIN ANALYSIS OF BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: MANUFACTURING AND DISTRIBUTION PHASES ADD MAXIMUM VALUE
  • 5.4 ECOSYSTEM ANALYSIS
    • FIGURE 25 ECOSYSTEM ANALYSIS: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET
    • TABLE 7 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: ROLE IN ECOSYSTEM
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.4 BARGAINING POWER OF BUYERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 TECHNOLOGY ANALYSIS
  • 5.7 REGULATORY ANALYSIS
    • 5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 REGULATORY SCENARIOS ACROSS DIFFERENT COUNTRIES/REGIONS
  • 5.8 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 14 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BIOTECHNOLOGY CMO SERVICES
    • 5.9.2 BUYING CRITERIA
    • FIGURE 27 KEY BUYING CRITERIA FOR END USERS
  • 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

6 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 15 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
  • 6.2 MANUFACTURING
    • 6.2.1 SHIFT TOWARD SINGLE-USE TECHNOLOGY TO DRIVE MARKET
    • TABLE 16 BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 17 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 18 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 20 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 FORMULATION & FILL-FINISH
    • 6.3.1 MOST CRITICAL ASPECT OF BIOLOGICS MANUFACTURING
    • TABLE 21 BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 22 NORTH AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 EUROPE: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 25 LATIN AMERICA: BIOTECHNOLOGY CONTRACT FORMULATION & FILL-FINISH SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.4 PACKAGING & LABELING
    • 6.4.1 FINAL CHECKPOINT BEFORE PRODUCT REACHES PATIENT
    • TABLE 26 BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 27 NORTH AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 28 EUROPE: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 30 LATIN AMERICA: BIOTECHNOLOGY CONTRACT PACKAGING & LABELING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.5 OTHER SERVICES
    • TABLE 31 OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 32 NORTH AMERICA: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 EUROPE: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 LATIN AMERICA: OTHER BIOTECHNOLOGY CONTRACT MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

7 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 36 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 BIOLOGIC DRUG SUBSTANCE MANUFACTURING
    • 7.2.1 INCREASING DEMAND FOR BIOTECHNOLOGY PRODUCTS TO DRIVE MARKET
    • TABLE 37 BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 EUROPE: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 41 LATIN AMERICA: BIOLOGIC DRUG SUBSTANCE MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 BIOLOGIC DRUG PRODUCT MANUFACTURING
    • 7.3.1 INCREASING R&D COST AND PROCESS COMPLEXITY PROMPTED SHIFT TOWARD CONTRACT MANUFACTURING FOR BIOLOGIC DRUG PRODUCTS
    • TABLE 42 BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 43 NORTH AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 EUROPE: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 LATIN AMERICA: BIOLOGIC DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)

8 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 8.1 INTRODUCTION
    • TABLE 47 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
  • 8.2 COMMERCIAL OPERATIONS
    • 8.2.1 INCREASING APPROVALS OF BIOLOGICS TO SUPPORT MARKET GROWTH
    • TABLE 48 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 50 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 CLINICAL OPERATIONS
    • 8.3.1 INCREASING NUMBER OF CLINICAL TRIALS FOR TARGETED THERAPIES TO DRIVE MARKET
    • TABLE 53 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 54 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 55 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 56 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

9 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE

  • 9.1 INTRODUCTION
    • TABLE 58 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
  • 9.2 MAMMALIAN EXPRESSION SYSTEMS
    • 9.2.1 VERSATILE THERAPEUTIC DIVERSITY TO DRIVE MARKET
    • TABLE 59 TYPES OF MAMMALIAN EXPRESSION SYSTEMS
    • TABLE 60 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 61 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 64 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 NON-MAMMALIAN EXPRESSION SYSTEMS
    • 9.3.1 INCREASING DEMAND FOR BIOLOGICS VACCINES TO SUPPORT MARKET GROWTH
    • TABLE 65 TYPES OF MICROBIAL EXPRESSION SYSTEMS AND THEIR APPLICATIONS
    • TABLE 66 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 68 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 69 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 70 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NON-MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2021-2028 (USD MILLION)

10 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE

  • 10.1 INTRODUCTION
    • TABLE 71 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
  • 10.2 MONOCLONAL ANTIBODIES
    • 10.2.1 GROWING APPROVALS FOR MABS TO PROPEL MARKET
    • FIGURE 28 NUMBER OF APPROVED MONOCLONAL ANTIBODIES, 2010-2022
    • TABLE 72 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 73 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 74 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 76 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.3 CELL & GENE THERAPIES
    • 10.3.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
    • TABLE 77 FDA-APPROVED CAR T-CELL THERAPIES
    • TABLE 78 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 79 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 82 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CELL & GENE THERAPIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.4 ANTIBODY-DRUG CONJUGATES
    • 10.4.1 INCREASING INVESTMENTS IN BIOLOGICS TO SUPPORT MARKET GROWTH
    • TABLE 83 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 84 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 85 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 86 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 87 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ANTIBODY-DRUG CONJUGATES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.5 VACCINES
    • 10.5.1 INCREASING DEMAND FOR VACCINES TO DRIVE MARKET
    • TABLE 88 NIH FUNDING FOR VACCINE RESEARCH, 2018-2022 (USD MILLION)
    • TABLE 89 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 90 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 91 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 93 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.6 THERAPEUTIC PEPTIDES & PROTEINS
    • 10.6.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS TO SUPPORT MARKET GROWTH
    • TABLE 94 EXAMPLES OF PEPTIDE THERAPEUTICS
    • TABLE 95 COMMERCIALIZED RECOMBINANT PROTEINS USED IN MEDICINE
    • TABLE 96 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 97 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 98 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR THERAPEUTIC PEPTIDES & PROTEINS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 10.7 OTHER MOLECULE TYPES
    • TABLE 101 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 102 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 103 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 105 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER MOLECULE TYPES, BY COUNTRY, 2021-2028 (USD MILLION)

11 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA

  • 11.1 INTRODUCTION
    • TABLE 106 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
  • 11.2 ONCOLOGY
    • 11.2.1 INCREASED APPROVALS AND LAUNCH OF BIOLOGICS FOR ONCOLOGY TO DRIVE MARKET
    • TABLE 107 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 108 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 109 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 110 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 111 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.3 AUTOIMMUNE DISEASES
    • 11.3.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET
    • TABLE 112 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 113 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 114 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 115 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 116 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.4 METABOLIC DISEASES
    • 11.4.1 INCREASING PREVALENCE OF METABOLIC DISEASES TO DRIVE ADOPTION OF BIOLOGICS
    • TABLE 117 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 118 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 119 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 120 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 121 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.5 CARDIOVASCULAR DISEASES
    • 11.5.1 DEVELOPMENT OF NEW TREATMENT OPTIONS TO SUPPORT MARKET GROWTH
    • TABLE 122 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 123 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 124 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 125 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 126 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.6 NEUROLOGY
    • 11.6.1 HIGH BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
    • TABLE 127 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 128 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 129 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 130 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 131 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR NEUROLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.7 INFECTIOUS DISEASES
    • 11.7.1 RISING EPIDEMIC OUTBREAKS TO SUPPORT MARKET GROWTH
    • TABLE 132 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 133 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 134 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 135 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 136 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 11.8 OTHER THERAPEUTIC AREAS
    • TABLE 137 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 138 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 139 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 140 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 141 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021-2028 (USD MILLION)

12 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 142 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 12.2 NORTH AMERICA
    • FIGURE 29 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SNAPSHOT
    • TABLE 143 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 144 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 145 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 146 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 147 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 148 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 149 NORTH AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.2.1 US
      • 12.2.1.1 Presence of large number of FDA-approved manufacturing facilities to favor market growth
    • TABLE 150 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 151 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 152 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 153 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 154 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 155 US: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.2.2 CANADA
      • 12.2.2.1 Rising government funding for drug development to support market growth
    • TABLE 156 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 157 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 158 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 159 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 160 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 161 CANADA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.2.3 RECESSION IMPACT
  • 12.3 EUROPE
    • TABLE 162 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 163 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 164 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 165 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 166 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 167 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 168 EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.3.1 GERMANY
      • 12.3.1.1 Rapidly growing pharmaceutical market to drive market
    • TABLE 169 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 170 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 171 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 172 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 173 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 174 GERMANY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.3.2 UK
      • 12.3.2.1 Rising investments in drug development to favor market growth
    • TABLE 175 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 176 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 177 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 178 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 179 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 180 UK: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.3.3 FRANCE
      • 12.3.3.1 Availability of funds from government and private organizations for domestic drug development to support market growth
    • TABLE 181 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 182 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 183 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 184 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 185 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 186 FRANCE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.3.4 ITALY
      • 12.3.4.1 Rising commercial drug development pipeline to drive market
    • TABLE 187 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 188 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 189 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 190 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 191 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 192 ITALY: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.3.5 SPAIN
      • 12.3.5.1 Rising R&D expenditure to propel market
    • TABLE 193 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 194 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 195 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 196 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 197 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 198 SPAIN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.3.6 REST OF EUROPE
    • TABLE 199 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 200 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 201 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 202 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 203 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 204 REST OF EUROPE: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.3.7 RECESSION IMPACT
  • 12.4 ASIA PACIFIC
    • FIGURE 30 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SNAPSHOT
    • TABLE 205 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 206 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 207 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 208 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 209 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 210 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 211 ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.4.1 CHINA
      • 12.4.1.1 Low manufacturing cost and high demand for medicines to favor market growth
    • TABLE 212 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 213 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 214 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 215 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 216 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 217 CHINA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.4.2 JAPAN
      • 12.4.2.1 Growing demand for biosimilars to drive growth
    • TABLE 218 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 219 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 220 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 221 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 222 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 223 JAPAN: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.4.3 SOUTH KOREA
      • 12.4.3.1 Increasing R&D activities for drug development to drive market
    • TABLE 224 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 225 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 226 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 227 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 228 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 229 SOUTH KOREA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.4.4 INDIA
      • 12.4.4.1 Increasing pharma R&D activities and government funding for biotechnology industry to support market growth
    • TABLE 230 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 231 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 232 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 233 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 234 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 235 INDIA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.4.5 REST OF ASIA PACIFIC
    • TABLE 236 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 237 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 238 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 239 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 240 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 241 REST OF ASIA PACIFIC: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.4.6 RECESSION IMPACT
  • 12.5 LATIN AMERICA
    • TABLE 242 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 243 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 244 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 245 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 246 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 247 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 248 LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.5.1 BRAZIL
      • 12.5.1.1 Growing pharmaceutical industry to drive market
    • TABLE 249 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 250 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 251 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 252 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 253 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 254 BRAZIL: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.5.2 REST OF LATIN AMERICA
    • TABLE 255 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 256 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 257 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 258 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 259 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 260 REST OF LATIN AMERICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.5.3 RECESSION IMPACT
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 GROWING PHARMACEUTICALS INDUSTRY TO SUPPORT MARKET GROWTH
    • TABLE 261 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021-2028 (USD MILLION)
    • TABLE 262 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 263 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION, 2021-2028 (USD MILLION)
    • TABLE 264 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY SOURCE, 2021-2028 (USD MILLION)
    • TABLE 265 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY MOLECULE TYPE, 2021-2028 (USD MILLION)
    • TABLE 266 MIDDLE EAST & AFRICA: BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA, 2021-2028 (USD MILLION)
    • 12.6.2 RECESSION IMPACT

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
    • FIGURE 31 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 13.2 REVENUE SHARE ANALYSIS
    • FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022
  • 13.3 MARKET SHARE ANALYSIS
    • FIGURE 33 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
    • TABLE 267 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEGREE OF COMPETITION
  • 13.4 COMPANY EVALUATION MATRIX
    • 13.4.1 STARS
    • 13.4.2 EMERGING LEADERS
    • 13.4.3 PERVASIVE PLAYERS
    • 13.4.4 PARTICIPANTS
    • FIGURE 34 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
  • 13.5 COMPETITIVE BENCHMARKING
    • 13.5.1 COMPANY FOOTPRINT ANALYSIS
    • TABLE 268 COMPANY FOOTPRINT ANALYSIS
    • 13.5.2 COMPANY FOOTPRINT ANALYSIS, BY MOLECULE TYPE
    • TABLE 269 MOLECULE TYPE FOOTPRINT ANALYSIS OF COMPANIES
    • 13.5.3 COMPANY FOOTPRINT ANALYSIS, BY REGION
    • TABLE 270 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES
  • 13.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 STARTING BLOCKS
    • 13.6.3 RESPONSIVE COMPANIES
    • 13.6.4 DYNAMIC COMPANIES
    • FIGURE 35 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
  • 13.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
    • TABLE 271 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
    • TABLE 272 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS
  • 13.8 COMPETITIVE SCENARIO AND TRENDS
    • 13.8.1 DEALS
    • TABLE 273 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: DEALS, JANUARY 2020-JULY 2023
    • 13.8.2 OTHER DEVELOPMENTS
    • TABLE 274 BIOTECHNOLOGY CONTRACT MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020-JULY 2023

14 COMPANY PROFILES

  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
  • 14.1 KEY PLAYERS
    • 14.1.1 LONZA
    • TABLE 275 LONZA: BUSINESS OVERVIEW
    • FIGURE 36 LONZA: COMPANY SNAPSHOT (2022)
    • 14.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 276 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
    • FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
    • 14.1.3 WUXI BIOLOGICS
    • TABLE 277 WUXI BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 38 WUXI BIOLOGICS: COMPANY SNAPSHOT (2022)
    • 14.1.4 CATALENT, INC.
    • TABLE 278 CATALENT, INC.: BUSINESS OVERVIEW
    • FIGURE 39 CATALENT, INC.: COMPANY SNAPSHOT (2022)
    • 14.1.5 SAMSUNG BIOLOGICS
    • TABLE 279 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 40 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
    • 14.1.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • TABLE 280 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
    • FIGURE 41 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
    • 14.1.7 FUJIFILM HOLDINGS CORPORATION
    • TABLE 281 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 42 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
    • 14.1.8 ABBVIE INC.
    • TABLE 282 ABBVIE INC.: BUSINESS OVERVIEW
    • FIGURE 43 ABBVIE INC.: COMPANY SNAPSHOT (2022)
    • 14.1.9 EUROFINS SCIENTIFIC
    • TABLE 283 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 44 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
    • 14.1.10 GENSCRIPT BIOTECH CORPORATION
    • TABLE 284 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW
    • FIGURE 45 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2022)
    • 14.1.11 AGC INC.
    • TABLE 285 AGC INC.: BUSINESS OVERVIEW
    • FIGURE 46 AGC INC.: COMPANY SNAPSHOT (2022)
    • 14.1.12 MERCK KGAA
    • TABLE 286 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 14.1.13 JSR CORPORATION
    • TABLE 287 JSR CORPORATION: BUSINESS OVERVIEW
    • FIGURE 48 JSR CORPORATION: COMPANY SNAPSHOT (2022)
  • 14.2 OTHER PLAYERS
    • 14.2.1 STELIS
    • 14.2.2 RECIPHARM AB
    • 14.2.3 EMERGENT
    • 14.2.4 SHANGHAI FOSUN PHARMACEUTICAL CO., LTD.
    • 14.2.5 LOTTE BIOLOGICS
    • 14.2.6 HEPALINK GROUP
    • 14.2.7 CURIA GLOBAL, INC.
    • 14.2.8 JRS PHARMA
    • 14.2.9 MINAPHARM PHARMACEUTICALS
    • 14.2.10 RENTSCHLER BIOPHARMA SE
    • 14.2.11 AVID BIOSERVICES, INC.
    • 14.2.12 ABZENA LTD.
    • 14.2.13 POLYPLUS TRANSFECTION
    • 14.2.14 MIDAS PHARMA GMBH
    • 14.2.15 MABPLEX INTERNATIONAL CO., LTD.
    • 14.2.16 ASAHI KASEI CORPORATION
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS